Open‐label prospective study of the safety and efficacy of glass‐based yttrium 90 radioembolization for infiltrative hepatocellular carcinoma with portal vein thrombosis

Publisher： John Wiley & Sons Inc

E-ISSN： 1097-0142|121|13|2164-2174

ISSN： 0008-543x

Source： CANCER, Vol.121, Iss.13, 2015-07, pp. : 2164-2174

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Treatment for Hepatocellular Carcinoma with Portal Vein Tumor Thrombosis: The Emerging Role for Radioembolization Using Yttrium-90

By  

Oncology, Vol. 84, Iss. 5, 2013-04 ,pp. : 311-318

Karger

Access to resources Recommend Favorite

UNBLOCK: an open‐label, dose‐finding, pharmacokinetic and safety study of bivalirudin in children with deep vein thrombosis

By  

JOURNAL OF THROMBOSIS AND HAEMOSTASIS, Vol. 13, Iss. 9, 2015-09 ,pp. : 1615-1622

John Wiley & Sons Inc

Access to resources Recommend Favorite

Yttrium‐90 radioembolization vs sorafenib for intermediate‐locally advanced hepatocellular carcinoma: a cohort study with propensity score analysis

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 3, 2015-03 ,pp. : 1036-1047

John Wiley & Sons Inc

Access to resources Recommend Favorite

In intermediate stage hepatocellular carcinoma: radioembolization with yttrium 90 or chemoembolization?

By  

LIVER INTERNATIONAL (ELECTRONIC), Vol. 35, Iss. 2, 2015-02 ,pp. : 627-635

John Wiley & Sons Inc

Access to resources Recommend Favorite

An Open-Label Extension Study to Evaluate Safety and Efficacy of Pazopanib in Patients with Advanced Renal Cell Carcinoma

By  

Oncology, Vol. 87, Iss. 6, 2014-09 ,pp. : 342-350

Karger

Access to resources Recommend Favorite